Skip to main content
editorial
. 2019 Aug 20;121(7):513–514. doi: 10.1038/s41416-019-0536-0

Table 1.

Novel androgen deprivation drugs. Summary data on three trials. (Modified from ref. 3–5)

SPARTAN
Jannsen		 PROSPER
Pfizer/Astellas		 ARAMIS
ORION/Bayer HealthCare
Apalutamide, Erleada Enzalutamide, Extandi® Darolutamide
graphic file with name 41416_2019_536_Figa_HTML.gif graphic file with name 41416_2019_536_Figb_HTML.gif graphic file with name 41416_2019_536_Figc_HTML.gif
Group A P E P D P
Patients, n 806 421 933 468 955 554
M-Fs, m 40 18 37 15 40 18
SAE’s, % 25 20 31 23 25 20
Discontinuation, % 11 7 10 6 9 9

All subjects were on continuous conventional androgen deprivation therapy. Values are rounded

A apalutamide, E enzalutamide, D, darolutamide, P placebo, M-FS metastasis-free survival, months, SAE’s serious adverse events